Biologic drugs have revolutionized treatment options for patients with cancer and chronic autoimmune disorders. However, amidst this positive climate, a growing and substantial problem exists in this era of personalized medicine: response to biologics varies by individual patient. The same dose of a drug can result in different amounts of effective drug circulating the blood stream, leading to unpredictable results. It is quite clear that one dose does not fit all - response varies and requires monitoring. Our assays based on robust mimetope peptides, termed Veritopes, will allow researchers and physicians to monitor and quantitate the amount of active biologic drug circulating in the blood. Moving forward, therapeutic dose monitoring is necessary for the optimal use of biologic drugs to ensure better patient outcomes. Abreos provides a robust, comprehensive, scalable, stable, inexpensive way to monitor biologic drugs. The Veritope™ technology enables the creation of a custom reagent, specific to a unique biologic target, that can rapidly and routinely detect biologic drug levels in individual patients – all with the objective of providing critical data to make appropriate dosing decisions for the patient.